Hikma Sharpens Focus On COVID-19 Demand
Maintains Financial Guidance Amid Coronavirus Challenges And Uncertainty
Executive Summary
Hikma says it is prioritizing the production and delivery of medicines that are in the highest demand amid the COVID-19 pandemic, as the firm has provided a trading update that maintains its sales forecasts in the face of “challenging market conditions” and uncertainty.